Colorectal Cancer

Scott Kopetz, MD, PhD, FACP, explains the purpose of the phase 1b KISIMA-01 study of the ATP128 vaccine used with or without with or without ezabenlimab to treat patients with advanced colorectal cancer.

In an interview with Targeted Oncology™, Michael J. Overman, MD, discussed targeted rare genomic alterations in colorectal cancer.

Preliminary results from the phase 1b KISIMA-01 indicate that combining the single chimeric fusion protein ATP128 with the PD-1 inhibitor, ezabenlimab, is tolerable in patients with heavily pretreated refractory stage IV colorectal cancer and may induce immune responses.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.

A biomarker analysis utilized liquid biopsies to find potential prognostic and predictive biomarkers for patients with BRAF V600E–mutant metastatic colorectal cancer treated with BRAF, EGFR, and/or MEK inhibitors.

Findings from the OCTOPUS Consortium of trial data have indicated that obese patients with colorectal cancer have a poorer survival from adjuvant chemotherapy treatment due to reduced treatment dose and average cumulative relative dose.

In a first-of-its-kind study, data reveal that unnecessary antibiotic use may increase the risk of colon cancer—especially in people under age 50. Findings were presented at the 2021 World Congress on Gastrointestinal Cancer.

Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.

The phase 3 KRYSTAL-10 trial continues to look at the combination of adagrasib and cetuximab in patients with previously treated advanced colorectal cancer and a KRAS G12C mutation in their tumor.

Results of a single-arm phase 2 study of regorafenib plus nivolumab in patients with mismatch repair–proficient/microsatellite stable colorectal cancer found a discrepancy in efficacy between the Japanese and North American Population.

Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

In the phase 2 PANAMA trial, adding panitumumab to 5-fluorouracil and leucovorin showed significant improvement in progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.

With addition 16-month follow-up, the benefit of fam-trastuzumab deruxtecan-nxki as treatment of patients with HER2-overexpressing metastatic colorectal cancer showed results that were consistent with the primary analysis of the DESTINY-CRC01 trial study.

The FOLFOXIRI regimen in combination with bevacizumab is preferred over FOLFOXIRI plus cetuximab for the treatment of patients with RAS wild type, BRAF V600E mutant metastatic colorectal cancer.

lenvatinib plus pembrolizumab elicited a response in some patients with advanced colorectal cancer.

The United States Preventive Services Task Force is recommending that individuals at average risk of colorectal cancer begin screening exams at age 45 rather than 50 years of age due to the risk of early on-set colorectal cancer.

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity and a consistent safety profile in patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild type, according to findings from the phase 2 LCCC1632 study.

A novel liquid biopsy test for the detection of lymph node metastasis in individuals with high-risk submucosal colorectal carcinoma has been developed.

The FDA has authorized the marking of GI Genius, the first device that uses artificial intelligence to assist in the diagnosis of colon cancer.

Physicians published a new analysis that challenges the FDA approval of pembrolizumab for patients with treatment-refractory cancers and a high tumor mutational burden.

The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.

Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.

The use of a fitness tracking device as a prognostic tool was feasible and acceptable in a study evaluating 80 patients with colorectal cancer.

The FDA has granted 2 breakthrough device designations to the molecular residual disease test, Signatera.